S. 934 - FDA Reauthorization Act of 2017

FDA Reauthorization Act of 2017

S. 934 — 115^th Congress (2017–2018)

Summary

A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes. (by CRS)

Learn More

At OpenCongress

Title

A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.

Other Titles

• FDA Reauthorization Act of 2017
• Biosimilar User Fee Amendments of 2017
• Generic Drug User Fee Amendments of 2017
• Medical Device User Fee Amendments of 2017
• Prescription Drug User Fee Amendments of 2017
• FDA Reauthorization Act of 2017
• FDA Reauthorization Act of 2017
• Biosimilar User Fee Amendments of 2017
• Biosimilar User Fee Amendments of 2017
• Generic Drug User Fee Amendments of 2017
• Generic Drug User Fee Amendments of 2017
• Medical Device User Fee Amendments of 2017
• Medical Device User Fee Amendments of 2017
• Prescription Drug User Fee Amendments of 2017
• Prescription Drug User Fee Amendments of 2017
• FDA Reauthorization Act of 2017

Sponsor

Lamar Alexander

Co-Sponsors

• Patty Murray

Subjects

• Health
• Administrative law and regulatory procedures
• Administrative remedies
• Alternative treatments
• Cancer
• Child health
• Computers and information technology
• Congressional oversight
• Department of Health and Human Services
• Drug safety, medical device, and laboratory regulation
• Drug therapy
• Executive agency funding and structure
• Food and Drug Administration (FDA)
• Fraud offenses and financial crimes
• Government buildings, facilities, and property
• Government information and archives
• Government studies and investigations
• Health information and medical records
• Health personnel
• Health technology, devices, supplies
• Hearing, speech, and vision care
• Infectious and parasitic diseases
• International organizations and cooperation
• Licensing and registrations
• Manufacturing
• Marketing and advertising
• Medical research
• Medical tests and diagnostic methods
• Performance measurement
• Prescription drugs
• Public contracts and procurement
• Public participation and lobbying
• Public-private cooperation
• Small business
• User charges and fees

Related Bills

• S. 1115 (115^th) : Making Pharmaceutical Markets More Competitive Act
• H.R. 2430 (115^th) : FDA Reauthorization Act of 2017
• S. 1069 (115^th) : Medical Device Safety Monitoring Act
• S. 1070 (115^th) : Realizing Intended Safety for Certain Accessories Act of 2017
• H.R. 2562 (115^th) : Making Pharmaceutical Markets More Competitive Act
• H.R. 1652 (115^th) : Over-The-Counter Hearing Aid Act of 2017
• S. 670 (115^th) : Over-The-Counter Hearing Aid Act of 2017
• S. 1049 (115^th) : Opioid Addiction Risk Transparency Act
• H.R. 2376 (115^th) : Drug Diversion and Counterfeit Crackdown Act of 2017
• S. 1062 (115^th) : FDA Reporting Transparency and Accountability Act
• S. 1048 (115^th) : Enhanced Clinical Trial Design Act of 2017
• S. 1093 (115^th) : Pediatric Device Development Act

Major Actions

Introduced	4/25/2017
Referred to Committee

Bill History

• All Votes
• All Actions
• Amendments

There have been no votes on this bill.

	Action	Date	Description
	Introduced	4/25/2017
		4/25/2017	Introduced in Senate
		4/25/2017	Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
	Put on a legislative calendar	5/11/2017	Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
		5/11/2017	Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.
	Put on a legislative calendar	5/11/2017	Placed on Senate Legislative Calendar under General Orders. Calendar No. 76.

	Number	Sponsor	Date Offered	Status